RECENT POSTS
- Your First Move For Wednesday November 10th
- Web Extra: The Best Trades In Tech
- Pops & Drops: UPS, Electronic Arts...
- Take Your Position: Retail Earnings
- The Return of Dividend Investing?
- Should You Believe in this Rally?
- Trading in this Technicals-Driven Market
- HALFTIME REPORT: How to Trade Senator Dodd's Financial Reforms
FAST MONEY FEATURES
FAST MONEY POLLGet in the post game. Respond to our "Question of the Day" right now.
TRADE SCHOOLGrab a pencil because school is in session and the Fast Money traders are teaching class.
FAST MONEY PODCASTSDownload Fast Money onto your MP3 Player.
FAST MONEY WIDGETGrab this all-in-one application and get recaps of the show sent right to your desktop or blog.
SHOP FOR FAST MONEY MERCHANDISEGet your game on with Fast Money gear.
FAST MONEY PHOTOS!Check out our scrapbook. These "pix" are guaranteed winners.
NEWSLETTERSign up and receive a recap email every Friday after the show!
FAST MONEY MOBILE ALERTSGet advanced information about the next Fast Money.
Text Size 
 |
For people struggling with diabetes, the bathroom scale can be the enemy. But a new drug may change all that.
Late results show an experimental Type 2 diabetes drug from Novo Nordisk [NVO
Loading...
()
] called liraglutide
led to greater reduction in blood sugar than Byetta, a rival medication sold by Amylin Pharmaceuticals [AMLN
Loading...
()
] and Eli Lilly [LLY
Loading...
()
].
And equally important -- among patients who completed the two-year trial, 58 percent of them lost an average of 6 pounds.
That's significant because some older diabetes medicines cause weight gain and many patients struggling with diabetes also tend to struggle with their weight.
Sounds like a winner but there are some health concerns. A recent advisory panel to the U.S. Food and Drug Administration was split on whether to recommend liraglutide approval over concern about thyroid tumors found in mice and rats tested with the medicine.
------------
And, as if Byetta needed any more headwinds – the venerable drug may have even more competition on the horizon.
New results show an experimental diabetes drug from GlaxoSmithKline [GSK
Loading...
()
] was also more effective than Byetta in controlling blood sugar.
The Glaxo drug, called Syncria, is entering Phase III testing; and it’s expected to take two to three years to complete.
We'll be watching.
- Your First Move For Wednesday November 10th
- Web Extra: The Best Trades In Tech
- Pops & Drops: UPS, Electronic Arts...
- Take Your Position: Retail Earnings
- The Return of Dividend Investing?
- Should You Believe in this Rally?
- Trading in this Technicals-Driven Market
- HALFTIME REPORT: How to Trade Senator Dodd's Financial Reforms
- Your First Move For Tuesday November 9th
- Web Extra: The Dow's Only Loser
______________________________________________________
Got something to to say? Send us an e-mail at and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to .
Trader disclosure: On June 8th, 2009, the following stocks and commodities mentioned or intended to be mentioned on CNBC’s Fast Money were owned by the Fast Money traders; Najarian Owns (BX) Call Spread; Najarian Owns (DELL) Call Spread; Najarian Owns (FCX) Calls & Put Spread; Najarian Owns (INTC) Call Spread; Najarian Owns (MCD) Call Spread; Najarian Owns (MOS) Put Spread; Najarian Owns (PALM) Call Spread; Najarian Owns (WNR); Najarian Owns (ISIS); Terranova Owns (TER), (XBI), (ABT), (RIMM), (BTU), (BRCM), (GENZ); Terranova Owns (MS) & (MS) Calls; Terranova Is Short (FCX) & (FCX) Puts; Terranova Owns (HES) & (HES) Calls; Terranova Owns (XOM) Call Spread ; Terranova Owns (DIS) Call Spread; Terranova Owns (X) & (X) Calls; Terranova Owns (JPM) & (JPM) Calls; Terranova Owns (POT) & (POT) Calls ; Adami Owns (AGU), (C), (GS), (INTC), (BTU), (MSFT), (NUE); Finerman Owns (BAC) Preferred; Finerman's Firm Own (NOK), (PBR), (RIG), (TBT), (WRC), (KFT); Finerman's Firm Owns (BAC) Preferred; Finerman's Firm Owns (WFC) Preferred; Finerman Owns (WFC) Preferred; Finerman's Firm Is Short (BAC)
CNBC.com with wires
Data is a real-time snapshot *Data is delayed at least 15 minutes